Prolactinoma-associated obesity treated with bupropion and methylphenidate.
作者信息
Terock Jan, Hohagen Fritz, Petersen Dirk, Zurowski Bartosz
机构信息
Department of Psychiatry and Psychotherapy, University of Lübeck, Ratzeburger Allee 160, Lübeck, 23538, Germany.
出版信息
Ther Adv Psychopharmacol. 2013 Jun;3(3):177-80. doi: 10.1177/2045125312467345.
Abstract
摘要
相似文献
1
Prolactinoma-associated obesity treated with bupropion and methylphenidate.用安非他酮和哌甲酯治疗与泌乳素瘤相关的肥胖症。
Ther Adv Psychopharmacol. 2013 Jun;3(3):177-80. doi: 10.1177/2045125312467345.
2
Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans.
Exp Clin Psychopharmacol. 1998 Feb;6(1):32-44. doi: 10.1037//1064-1297.6.1.32.
3
Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155).在健康志愿者中，经过长时间使用后，安非他酮与哌甲酯相比的心理和生理影响（NCT00285155）。
Eur J Clin Pharmacol. 2013 Apr;69(4):779-87. doi: 10.1007/s00228-012-1418-z. Epub 2012 Oct 9.
4
Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study.安非他酮与哌甲酯治疗儿童注意力缺陷/多动障碍的随机双盲研究
Hum Psychopharmacol. 2012 Jul;27(4):411-8. doi: 10.1002/hup.2242.
5
Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder.
J Am Acad Child Adolesc Psychiatry. 1995 May;34(5):649-57. doi: 10.1097/00004583-199505000-00017.
6
Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults.安非他酮缓释片、哌甲酯与安慰剂治疗成人注意力缺陷多动障碍的对比研究
Ann Clin Psychiatry. 2001 Sep;13(3):129-34. doi: 10.1023/a:1012239823148.
7
Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.比较托莫西汀、利斯的明、安非他酮和哌甲酯治疗儿童和青少年注意缺陷多动障碍的疗效和可接受性：一项关注安非他酮的荟萃分析。
J Affect Disord. 2015 Jun 1;178:149-59. doi: 10.1016/j.jad.2015.03.006. Epub 2015 Mar 13.
8
A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.安非他酮用于儿童和青少年注意力缺陷/多动障碍的系统评价
J Child Adolesc Psychopharmacol. 2017 Mar;27(2):112-116. doi: 10.1089/cap.2016.0124. Epub 2016 Nov 4.
9
Pharmacokinetic interactions between cyclosporine and bupropion or methylphenidate.环孢素与安非他酮或哌甲酯之间的药代动力学相互作用。
J Child Adolesc Psychopharmacol. 2001 Summer;11(2):193-8. doi: 10.1089/104454601750284117.
10
Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder.哌甲酯和安非他酮对注意力缺陷多动障碍患者血浆脱氢表雄酮硫酸盐（DHEA-S）和皮质醇水平的影响。
Child Psychiatry Hum Dev. 2008 Jun;39(2):201-9. doi: 10.1007/s10578-007-0081-6. Epub 2007 Aug 31.
本文引用的文献
1
Effects of methylphenidate on weight gain and food intake in hypothalamic obesity.哌醋甲酯对下丘脑性肥胖体重增加和食物摄入的影响。
Front Endocrinol (Lausanne). 2011 Dec 14;2:78. doi: 10.3389/fendo.2011.00078. eCollection 2011.
2
Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.卡麦角林（一种多巴胺受体激动剂）随机先导研究：对肥胖成年人体重和葡萄糖耐量的影响。
Diabetes Obes Metab. 2012 Apr;14(4):335-40. doi: 10.1111/j.1463-1326.2011.01534.x. Epub 2011 Dec 27.
3
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.泌乳素瘤患者在使用多巴胺激动剂治疗前后的 BMI 和代谢特征。
Obesity (Silver Spring). 2011 Apr;19(4):800-5. doi: 10.1038/oby.2010.150. Epub 2010 Jun 17.
4
Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats.肥胖大鼠成瘾样奖励功能障碍和强迫性进食中的多巴胺 D2 受体。
Nat Neurosci. 2010 May;13(5):635-41. doi: 10.1038/nn.2519. Epub 2010 Mar 28.
5
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.比较联合使用安非他酮和纳曲酮治疗肥胖症与单药治疗和安慰剂的效果。
J Clin Endocrinol Metab. 2009 Dec;94(12):4898-906. doi: 10.1210/jc.2009-1350. Epub 2009 Oct 21.
6
Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion.用安非他酮成功治疗的吸烟者中线索诱导的吸烟欲望和大脑奖励活动的减弱。
J Psychopharmacol. 2010 Jun;24(6):829-38. doi: 10.1177/0269881109105456. Epub 2009 Jul 31.
7
Rational design of a combination medication for the treatment of obesity.用于治疗肥胖症的复方药物的合理设计。
Obesity (Silver Spring). 2009 Jan;17(1):30-9. doi: 10.1038/oby.2008.461. Epub 2008 Nov 6.
8
Cabergoline-induced psychotic exacerbation in schizophrenic patients.卡麦角林诱发精神分裂症患者精神病性症状加重
Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):378-80. doi: 10.1016/j.genhosppsych.2007.11.002.
9
Widespread reward-system activation in obese women in response to pictures of high-calorie foods.肥胖女性在看到高热量食物图片时，其奖赏系统会出现广泛激活。
Neuroimage. 2008 Jun;41(2):636-47. doi: 10.1016/j.neuroimage.2008.02.031. Epub 2008 Mar 4.
10
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.多巴胺能张力与肥胖：来自用溴隐亭治疗的催乳素瘤的见解。
Eur J Endocrinol. 2002 Jul;147(1):77-84. doi: 10.1530/eje.0.1470077.
Zotero 插件